Drug Abuse Treatment Development and Research Mentoring

药物滥用治疗开发和研究指导

• 批准号: 7180794
• 负责人: Edward V. Nunes
• 金额: $ 17.7万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7180794
• 关键词: Abstinence; Academy; Address; Adolescent; Adolescent Psychiatry; Adult; Age; Aggressive behavior; Agonist; Alcohol abuse; Alcohol dependence; Alcohol or Other Drugs use; Alcoholic Beverages; Alcohols; American; Amino Acids; Anticonvulsants; Antidepressive Agents; Anxiety; Appendix; Archives; Area; Attention; Attention deficit hyperactivity disorder; Award; Behavior; Behavior Disorders; Behavior Therapy; Behavioral; Behavioral Research; Biography; Biological; Biology; Biometry; Brain; Buprenorphine; Cannabis; Categories; Caucasians; Caucasoid Race; Cerebrum; Chairperson; Child; Child Psychiatry; Childhood; Chronic; Class; Clinic; Clinical; Clinical Psychology; Clinical Research; Clinical Trials Network; Clonidine; Cocaine; Cocaine Dependence; Cognitive; Cognitive Therapy; Cohort Studies; Collaborations; Combined Modality Therapy; Communities; Confidence Intervals; DSM-IV; DSM-V; Daily; Data; Data Set; Dependence; Depressed mood; Depression screen; Depressive Syndromes; Depressive disorder; Desipramine; Development; Dextroamphetamine; Diagnosis; Diagnostic; Diagnostic Procedure; Directories; Disease; Doctor of Philosophy; Dopamine; Dorsal; Dose; Dropout; Drug Addiction; Drug Formulations; Drug Metabolic Detoxication; Drug abuse; Drug usage; Early Intervention; Early identification; Educational process of instructing; Effectiveness; Elevation; Emotional; Environment; Evaluation; Evidence based treatment; Faculty; Failure; Family; Feeling suicidal; Fellowship; Fellowship Program; First Degree Relative; Fluoxetine; Follow-Up Studies; Fostering; Foundations; Free Will; Freedom; Functional disorder; Funding; Future; Geriatric Psychiatry; Glucose; Glutamates; Goals; Grant; Grant Review; Guidelines; HIV; Health Personnel; Health system; Heterogeneity; Hospitals; Housing; Image; Imipramine; Impairment; Incentives; Injectable; Injection of therapeutic agent; Inpatients; Institute of Medicine (U.S.); Institutes; Intervention; Interview; Journals; K-Series Research Career Programs; Laboratories; Laboratory Animals; Lead; Leadership; Life; Link; Long Island; Maintenance; Major Depressive Disorder; Manuals; Marijuana Dependence; Measures; Medical; Medical Residency; Memantine; Memory; Mental Depression; Mental Health; Mental disorders; Mentored Clinical Oncology Award; Mentored Clinical Scientist Award; Mentored Patient-Oriented Research Career Development Award; Mentors; Mentorship; Meta-Analysis; Metabolic; Metabolism; Methadone; Methods; Mid-Career Clinical Scientist Award (K24); Modeling; Modification; Molecular Genetics; Monitor; Mood Disorders; Moods; Morbidity - disease rate; N-Methylaspartate; Naltrexone; National Institute of Drug Abuse; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Negative Reinforcements; Neurologic; Neurosciences; New York; Numbers; Object Attachment; Opiate Addiction; Opioid; Oral; Other Working Groups; Outcome; Outpatients; Overdose; Pain; Parent-Child Relations; Parents; Pathological Gambling; Patient Self-Report; Patients; Pattern; Peer Review; Pharmaceutical Preparations; Pharmacological Treatment; Pharmacotherapy; Physician Executives; Physicians; Placebo Control; Placebo Effect; Placebos; Plant Roots; Population; Positioning Attribute; Positron-Emission Tomography; Post-Traumatic Stress Disorders; Postdoctoral Fellow; Pre-Clinical Model; Prevalence; Preventive Intervention; Principal Investigator; Procedures; Process; Protocols documentation; Provider; Psychiatric Diagnosis; Psychiatrist; Psychiatry; Psychological reinforcement; Psychologist; Psychopathology; Psychotherapy; Publications; Published Comment; Published Directory; Punishment; Raclopride; Range; Rate; Recommendation; Recording of previous events; Recruitment Activity; Relapse; Relaxation; Relaxation Techniques; Relaxation Therapy; Reporting; Research; Research Ethics Committees; Research Institute; Research Personnel; Research Priority; Residencies; Residential Treatment; Resistance; Resources; Rest; Review Committee; Rewards; Risk; Risk Factors; Risk Reduction; Role; Sampling; Scanning; Schizophrenia; School-Age Population; Schools; Science; Scientist; Score; Screening procedure; Self Medication; Series; Serotonin; Sertraline; Services; Side; Site; Social Work; Sorting - Cell Movement; Source; Staging; Stress; Structure; Students; Subgroup; Substance Addiction; Substance abuse problem; Substance-Related Disorders; Support of Research; Symptoms; Syndrome; System; TNFRSF5 gene; Techniques; Technology Transfer; Testing; Thinking; Time; Toxic effect; Training; Training Activity; Translational Research; Trauma; Treatment Protocols; Tricyclic Antidepressive Agents; Universities; Urine; Vertical Disease Transmission; Week; Withdrawal; Woman; Work; addiction; alcohol seeking behavior; base; career; chronic pain; cingulate cortex; clinically significant; critical developmental period; day; depressive symptoms; design; disorder later incidence prevention; dopaminergic neuron; early onset; editorial; effectiveness trial; experience; follower of religion Jewish; gabapentin; improved; interest; member; mental disorder diagnosis; motivational enhancement therapy; nefazodone; neuropsychological; next generation; north shore long island; novel; outcome forecast; outreach; patient oriented research; placebo controlled study; pre-doctoral; prescription document; prescription procedure; professor; prognostic; programs; psychosocial; research to practice; response; reward circuitry; science education; size; skills; symposium; theories; therapy development; tiagabine; tool; topiramate; training project; treatment effect; treatment planning; treatment program; trend; valproate; voucher

DESCRIPTION (provided by applicant): The goal of this K24 Mid-Career Clinician-Scientist proposal is to allow the Candidate, Dr. Edward Nunes, to continue to expand his program of research and research mentorship in the field of drug abuse treatment development. The Candidate's research program focuses on two related themes, the treatment of co-occurring psychopathology in substance dependent patients, and the development of combinations of behavioral and pharmacological treatments for drug dependence. Major activities and accomplishments have included a series of studies examining the efficacy of antidepressant medications for treatment of opioid, cocaine, and alcohol dependent patients with depression, projects applying advances in behavioral therapies to naltrexone maintenance for opioid dependence and to treatment of depression among methadone maintained patients, applications of behavioral therapy to enhance the design of cocaine medications development trials, and multi-site effectiveness trials in the NIDA Clinical Trials Network. Through collaborations and the work of colleagues Dr. Nunes has, and continues to mentor, his agenda has expanded to examine structured psychiatric diagnostic methods, HIV risk reduction, and other co-occurring psychopathology including attention deficit hyperactivity disorder, impulsive aggression, post-traumatic stress disorder, pathological gambling, neuropsychological functioning, and childhood psychopathology and risk for drug dependence. Over the course of the proposed K24 Dr. Nunes will serve as Principle Investigator on a Center Project, two R01s, and the Long Island Node of the Clinical Trials Network, and as Co-l, Sponsor, or Co-Sponsor on funded projects of junior colleagues and mentored K awards. In particular the K24 will free Dr. Nunes' time and provide resources to pursue the development of new initiatives and collaborations in treatment research and to create opportunities in patient-oriented research for junior colleagues. The mentoring plan will serve young investigators at three main levels, 1) junior faculty with early or emerging independent research programs many of whom Dr. Nunes has mentored since fellowship or during K awards, 2) three current K23 awardees for whom Dr. Nunes serves as Sponsor, and three current (or anticipated) K23 or K01 awardees for whom he serves as Co-Sponsor or Consultant, and 3) Post doctoral fellows in clinical research in the Department's NIDA funded T32 research fellowship program. In addition Dr. Nunes will seek to foster independent research initiatives and collaborations involving the clinical leadership of community-based treatment programs participating in the Clinical Trials Network. The ultimate goals are to improve the treatment of drug dependent patients through clinical research and to help foster the next generation of clinician-researchers.

描述（由申请人提供）：本K24中期职业临床医生-科学家提案的目标是允许候选人Edward Nunes博士继续扩大其在药物滥用治疗开发领域的研究和研究指导计划。候选人的研究计划侧重于两个相关的主题，物质依赖患者共同发生的精神病理学的治疗，以及药物依赖的行为和药理学治疗组合的发展。主要活动和成就包括一系列研究，检查抗抑郁药物治疗阿片类药物，可卡因和酒精依赖性抑郁症患者的疗效，将行为疗法的进展应用于阿片类药物依赖的纳洛酮维持和美沙酮维持患者的抑郁症治疗的项目，行为疗法的应用，以加强可卡因药物开发试验的设计，和NIDA临床试验网络中的多中心有效性试验。通过合作和同事的工作Nunes博士已经并继续指导，他的议程已经扩展到检查结构化的精神病学诊断方法，艾滋病毒风险降低，以及其他共同发生的精神病理学，包括注意缺陷多动障碍，冲动性攻击，创伤后应激障碍，病理性赌博，神经心理功能，以及儿童精神病理学和药物依赖风险。在拟议的K24过程中，Nunes博士将担任一个中心项目，两个R 01和临床试验网络长岛节点的主要研究者，并担任初级同事和指导K奖资助项目的Co-l，赞助商或共同赞助商。特别是K24将释放Nunes博士的时间，并提供资源，以追求治疗研究的新举措和合作的发展，并为初级同事创造以患者为导向的研究机会。该指导计划将在三个主要层次为年轻的研究人员服务，1）具有早期或新兴独立研究项目的初级教师，其中许多人自奖学金或K奖期间就曾指导过Nunes，2）三名现任K23获奖者，Nunes博士担任赞助商，以及三名现任K23获奖者。（或预期）K23或K 01获奖者，他担任共同赞助商或顾问，以及3）在该部门的NIDA资助的T32研究奖学金计划的临床研究博士后研究员。此外，Nunes博士将寻求促进独立的研究计划和合作，包括参与临床试验网络的社区治疗项目的临床领导。最终目标是通过临床研究改善药物依赖患者的治疗，并帮助培养下一代临床研究人员。